Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion

Regeneron Announces FDA Acceptance of EYLEA® (aflibercept) Injection Supplemental Biologics License Application for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion

[PR Newswire] – TARRYTOWN, N.Y., Feb. 24, 2014 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company’s supplemental Biologics License Applicati more

View todays social media effects on REGN

View the latest stocks trending across Twitter. Click to view dashboard

See who Regeneron is hiring next, click here to view

Share this post